Anygen 

Anygen Co., Ltd., a bio-venture company, engages in the manufacture of peptide APIs and drug development in South Korea and internationally. The company develops GMP, generic, custom, and catalog peptides, as well as offers other services. It is also developing AGM-130 for breast cancer; AGM-212 for type 2 diabetes; AGM-251 for neuropathic pain; and AGM-290 for MRSA infection treatment. The company was founded in 2000 and is headquartered in Gwangju, South Korea.